Merus

Latest Posts

Petosemtamab together with pembrolizumab in 1L r/m PD-L1 expressing HNSCC ongoing with medical knowledge...

Market

Merus’ Petosemtamab Monotherapy Interim Knowledge Continues to Reveal Clinically Significant Exercise in 2L+ r/m HNSCC By Investing.com

UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 02, 2024 (GLOBE NEWSWIRE) -- Merus N.V....

Market

Merus Presents Interim Information on MCLA-145 Monotherapy and in Mixture with Pembrolizumab on the 2024 ASCO ® Annual Assembly By Investing.com – Coin Trolly